Subacute administration of a TRH analogue (RX77368) in motor neuron disease: an open study

H MODARRES-SADEGHI, H ROGERS, J EMAMI, R J GUILLOF

From the Department of Neurology, Charing Cross and Westminster Medical School, Westminster Hospital, London, UK

SUMMARY Sixteen patients with motor neuron disease received RX77368, a TRH analogue, IV, repeatedly over 1–12 weeks (median 2 weeks). Slight to moderate improvement in bulbar function, particularly speech, was reproduced or persisted with repeated infusions in 8 of 12 responders over a median of 18 days (range 14–90) during the period of study. Cramps (5/9) and spasticity (5/8) improved for a median of 14 days (range 7–35) and 7 days (range 2–14) respectively. The highest benefit/side effect ratio was seen with 0.2 mg/kg (0.15 mg/kg in those with severe bulbar palsy) every 3–4 days. Long term studies with this analogue in MND are indicated.

The background to the experimental use of thyrotropin releasing hormone (TRH) and analogues in clinical trials in motor neuron disease (MND) has been reviewed recently.1 It includes: (1) the presence of TRH in close proximity to motor neurons in the ventral horns of the spinal cord, probably in axonal terminals from descending projections from the brain stem raphe nuclei, (2) the existence of TRH receptors in lamina IX in the ventral horns. In MND its density and distribution is altered with a marked decrease in laminae IX–II (3) Electrophysiological data suggesting an excitatory action of TRH and analogues, probably of a neuromodulatory kind, on anterior horn cells, (4) Neuropharmacological evidence for a role of TRH in motor activity, (5) Beneficial effects of TRH and the analogue CG3509 on the outcome of experimental spinal cord injury, (6) a possible “ trophic” effect of TRH on spinal cord cultures and in reducing sciatic neuraxotomy-induced neuronal loss in the spinal cord of infant rats, (7) reported evidence of transient beneficial effects of TRH in experimental and human spinocerebellar degenerations.

The first report of high dose IV TRH in MND2 indicated that the beneficial effects seen on weakness, speech, swallowing, cramps, respiration and spasticity were short lived and that marked side effects were seen at the doses used. Trials of TRH analogues with more promising neuropharmacological actions, longer half-life and higher benefit/side effect ratio were suggested.

In a double blind, randomised placebo controlled study in 25 patients with MND3 we showed transient improvement in bulbar functions, decrease in spasticity and changes in muscle force following a single IV dose of RX77368, a stabilised TRH analogue. The longer term effects of this analogue are unknown. The purpose of this open study was to find out (1) The optimum dose and frequency of administration, (2) if the improvements seen can be maintained with acceptable or no side effects and (3) if there are any longer term side effects.

Materials and methods

Sixteen patients with MND were studied. The criteria for diagnosis and severe incapacity have previously been described.3 The first seven patients were responders in previous acute studies, the rest were consecutive patients. Relevant clinical details are summarised in table 1. All patients were admitted to hospital and gave informed consent. The study was approved by the local ethical committee.

RX77368 was provided by Reckitt and Colman Pharmaceutical Division, Hull, UK. The patients received 0.1–0.35 mg/kg intravenously by an infusion pump (Secura 871704/4). The dose was increased when no response was seen with minimal or no side effects. It was reduced if there were excessive side effects, clinical deterioration or in order to find the minimum dose producing beneficial effects. The dose was changed in 0.05–0.1 mg/kg steps. No further infusions were given when information about dose, dose interval and reproducibility of response was satisfactory. The first six patients received daily infusions over 6 hours for 7–10 days. The remainder received two to seven 2 hour infusions over 1–12 weeks (table 1) with changes in dose...
frequency according to the duration of the response seen. Three patients received in addition, blindly, saline infusions during this period.

Neurological examination included detailed assessment of muscle force both with the MRC scale and dynamometry and of muscle tone and fasciculations as previously described. The muscle groups tested by dynamometry included neck flexion (NF), shoulder abduction (SA), elbow flexion and extension (EF and EE), wrist extension (WE), finger extension (FE), index finger abduction (IFA), thumb abduction (TA), hip flexion (HF), knee extension (KE) and foot dorsiflexion (FD). Very weak or strong muscles were not tested by this method. For further analysis the muscle groups tested have been classified in proximal (SA, EF, EE, HF, KE), distal (WE, WE, IF, TA, FD), axial (NF), flexor (EF, HF, FD, NF), extensor (EE, WE, WE, KE), upper and lower limbs and hand muscles. Forced vital capacity (VC) was measured with a Wright (Mark 20) respirometer or a portable electronic spirometer. Peak flow (PF) was measured with a Wright peak flow meter. Maximal expiratory and inspiratory pressure (MEP, MIP) were measured with a specially designed instrument described previously. These measurements could not be reliably performed in two cases (Nos 10 and 11) with severe bulbar palsy. Bulbar function was also studied in patients with dysarthria by timed measurements of (1) protrusion and lateral movements of the tongue, 10 times each, (2) jaw movements (opening and closing the mouth 10 times), (3) repetition of the words “pepper” and “ticker” 10 times, (4) Maximal sustained elevation of the palate. They were performed in 11 patients except the last test which was done in seven patients. Toned activities of daily living (ADL) tested included zipping, managing buttons, opening and closing a door, picking up coins, writing a sentence, rising from a chair, and walking 10 yards. They were performed in eight cases, except the last two which were performed in nine. Others had no disability in the limbs or were unable to perform the tests.

The tests were standardised for each individual. To overcome learning effects they were performed repeatedly in the first 2 days. For all quantitative measurements three replications were obtained at each assessment. For maximal isometric voluntary contraction (MVC), respiratory and timed bulbar measurements, eight to 12 baseline assessments were taken over 6–10 days, followed by daily to twice daily (6 and 24 hours after the beginning of infusions) assessments during the infusions period and for a minimum of 1 week after the last infusion. For ADL six baseline assessments over a week were taken and then they were repeated at approximately weekly intervals and 1 week after the last infusion.

Change in speech was scored (0 = nil, 1 = subjective, 2 = also noticed by close relatives and doctor, 3 = also noticed by others). In addition change in range of jaw, tongue, palate and facial movements was scored by observation (slight, moderate, marked). Swallowing was scored by observation and palpation in a scale from 0 (none) to 5 (normal). Cramps were also scored (0 = nil, 1 = occasional, 2 = moderate at night and/or day, 3 = frequent day and night).

Temperature, pulse rate and blood pressure were monitored daily. A full general medical examination and chest radiograph, ECG, FBC, urea and electrolytes, liver function tests, Ca ++, phosphate and thyroid function tests were done before and after the infusion period. Thyroid function was also monitored weekly during the infusions.

In addition to recording the patient’s subjective response and qualitative clinical assessments, quantitative data were analysed by the following methods:

**Method A** A value outside 2 SD of mean baseline was accepted as a significant change. The best of three replications at each assessment was taken. Improvement or deterioration for each parameter was defined as at least two values with significant change in the first 3 days following

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age-sex</th>
<th>Clinical form</th>
<th>Norris scale</th>
<th>Time to severe incapacity</th>
<th>Duration of illness</th>
<th>Bulbar palsy</th>
<th>Tone UL-LL</th>
<th>Weakness UL-LL</th>
<th>Main disability</th>
<th>Dose mg/kg/infusion</th>
<th>No of infusions (Wks)</th>
<th>Period of infusion (Wks)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>57M</td>
<td>B</td>
<td>83</td>
<td>—</td>
<td>14</td>
<td>++</td>
<td>N</td>
<td>0–0</td>
<td>Dysarthria</td>
<td>0.10–0.20 (D)</td>
<td>10</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>65M</td>
<td>B</td>
<td>93</td>
<td>—</td>
<td>36</td>
<td>++</td>
<td>N</td>
<td>0–0</td>
<td>Dysarthria</td>
<td>0.20–0.25 (D)</td>
<td>10</td>
<td>2</td>
</tr>
<tr>
<td>3</td>
<td>34M</td>
<td>ALS</td>
<td>27</td>
<td>16</td>
<td>30</td>
<td>++</td>
<td>S₂–S₃</td>
<td>3–3</td>
<td>Tetraplegia</td>
<td>0.10–0.25 (D)</td>
<td>10</td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td>73M</td>
<td>ALS</td>
<td>46</td>
<td>13</td>
<td>19</td>
<td>++</td>
<td>H–S₂</td>
<td>2–3</td>
<td>Dysarthria</td>
<td>0.20–0.30 (D)</td>
<td>7</td>
<td>1–5</td>
</tr>
<tr>
<td>5</td>
<td>66M</td>
<td>ALS</td>
<td>89</td>
<td>—</td>
<td>36</td>
<td>–</td>
<td>H–N</td>
<td>2–0</td>
<td>Arm weakness</td>
<td>0.20–0.35 (D)</td>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>6</td>
<td>60M</td>
<td>ALS</td>
<td>73</td>
<td>—</td>
<td>60</td>
<td>–</td>
<td>H–N</td>
<td>2–0</td>
<td>Arm weakness</td>
<td>0.25–0.30 (D)</td>
<td>10</td>
<td>2</td>
</tr>
<tr>
<td>7</td>
<td>54M</td>
<td>ALS</td>
<td>57</td>
<td>36</td>
<td>72</td>
<td>+</td>
<td>H–H</td>
<td>2–3</td>
<td>Paraplegia</td>
<td>0.20–0.25 (V)</td>
<td>6</td>
<td>12</td>
</tr>
<tr>
<td>8</td>
<td>43M</td>
<td>ALS</td>
<td>49</td>
<td>36</td>
<td>42</td>
<td>+</td>
<td>N–S₂</td>
<td>2–2</td>
<td>Tetraparesis</td>
<td>0.20–0.30 (V)</td>
<td>7</td>
<td>4</td>
</tr>
<tr>
<td>9</td>
<td>63F</td>
<td>ALS</td>
<td>73</td>
<td>—</td>
<td>24</td>
<td>++</td>
<td>N</td>
<td>1–0</td>
<td>Dysarthria</td>
<td>0.15–0.25 (V)</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>10</td>
<td>57F</td>
<td>B</td>
<td>88</td>
<td>13</td>
<td>18</td>
<td>++</td>
<td>N</td>
<td>1–0</td>
<td>Dysarthria</td>
<td>0.10–0.20 (V)</td>
<td>6</td>
<td>4</td>
</tr>
<tr>
<td>11</td>
<td>36F</td>
<td>ALS</td>
<td>22</td>
<td>3</td>
<td>14</td>
<td>++</td>
<td>S₂–S₃</td>
<td>3–3</td>
<td>Tetraplegia</td>
<td>0.20–0.25 (V)</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>12</td>
<td>53F</td>
<td>ALS</td>
<td>60</td>
<td>12</td>
<td>18</td>
<td>–</td>
<td>H–S₂</td>
<td>3–1</td>
<td>Anarthria</td>
<td>0.10–0.20 (V)</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>13</td>
<td>60M</td>
<td>ALS</td>
<td>70</td>
<td>—</td>
<td>7</td>
<td>–</td>
<td>N–N</td>
<td>1–2</td>
<td>Paraparesis</td>
<td>0.20–0.30 (V)</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>14</td>
<td>61M</td>
<td>B</td>
<td>27</td>
<td>11</td>
<td>17</td>
<td>++</td>
<td>S₂–S₃</td>
<td>2–2</td>
<td>Dysarthria</td>
<td>0.10–0.20 (V)</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>15</td>
<td>45M</td>
<td>ALS</td>
<td>73</td>
<td>—</td>
<td>10</td>
<td>++</td>
<td>S₂–S₃</td>
<td>2–0</td>
<td>Tetraplegia</td>
<td>0.15–0.30 (V)</td>
<td>6</td>
<td>2–5</td>
</tr>
<tr>
<td>16</td>
<td>50F</td>
<td>ALS</td>
<td>78</td>
<td>12</td>
<td>17</td>
<td>+</td>
<td>N–S₁</td>
<td>1–3</td>
<td>Paraplegia</td>
<td>0.20–0.30 (V)</td>
<td>4</td>
<td>2</td>
</tr>
</tbody>
</table>

ALS = Amyotrophic lateral sclerosis; B = Bulbar, Bulbar palsy: + = mild, ++ = moderate, +++ = severe, +++++ = anarthric; UL = upper limb; LL = Lower limb; D = Daily; V = Variable dose interval; Weakness (per most affected limb): 0 = Nil, 1 = Mild, 2 = Moderate, 3 = Severe; Tone: N = Normal, H = Hypotonia, S = Spasticity (S₂ = Mild, S₃ = Moderate, S₄ = Severe). Time in months.

---

Subacute administration of a TRH analogue (RX77368) in motorneuron disease: an open study

Table 1 Clinical features of patients treated with RX77368
Bulbar function baselines in all patients tested. X axis = assessment number. Y axis = SI units. The baselines for each patient are identified by the code at the bottom. The function tested is identified for each graph: TL = tongue lateral movement; TP = tongue protrusion; JAW = jaw movement; PEP and TIC = repetition of words pepper and ticker; PF = peak flow; VC = vital capacity; MIP and MEP = maximal inspiratory and expiratory pressures. Each assessment is the best of 3 replications (Method A).

Infusions. Bulbar function baselines in all patients are shown in fig 1. For patients with a change in bulbar function mean baseline and SD is given in table 2. To allow comparison of the degree of change in different patients with widely different baselines, results were expressed as percentage change from mean baseline. To give an idea of the absolute change in each patient and allow comparison between different patients the change was also expressed as SD units from mean baseline (table 2). Bulbar functions were also analysed by the following three methods.

Method B All values during baseline, infusion and post infusion periods were considered as a stationary time series (after first differencing of the series were performed). A cumulative sum test (Datafit, Oxford University Press) was used to analyse the time series for each bulbar function in each patient at a probability level of alpha = 0.05 to detect a 1 SD difference from mean baseline. Significant breaks in the time series in the appropriate direction have been classified as improvement or deterioration. A recursive coefficient was also computed for the mean of the series at each assessment point. This method has allowed individualised correction of learning effects (fig 2).

Method C For each bulbar parameter in each patient the effect of all (C1), or individual infusions (C2) on the course of the whole time series was investigated by running a series of regressions. Dummy variables, d = 0 if no infusion and d = 1 for the first three values after each infusion were used. t statistics were calculated to evaluate the significance (p < 0.05) of the dummy variables in each regression.

Six measures of agreement (P0, P1, P2, A, x and K) were used to compare the results of methods B, C1 and C2 with method A.

Results

Twelve of 16 patients reported some subjective benefit from the drug. The main improvements were in
Subacute administration of a TRH analogue (RX77368) in motorneuron disease: an open study

Fig. 2 Learning effect. Cumulative sum. Tongue protrusion (Case 8). Left column: without removing learning effects. Right column: after removing learning effects from baseline. Upper graphs: Y axis = cumsum of residuals with respect to mean baseline shown for the whole time series. X axis = serial number in the time series. The arrows indicate first and last infusion. Baseline period = 10 days. Post infusion period = 7 days. The V-shaped lines represent critical bounds at 5% significance level for 1 SD from mean baseline. Lower graphs: Y axis plots the difference of each value from the mean of the process to that point. The upper left graph shows a significant structural break in the time series by point 13, that is, the csum falls below critical bounds suggesting improvement (less time to perform the test). However, the lower left graph shows a steady decline in the mean of the process during baseline indicating that a significant learning effect was present. The right upper plot shows that when each 1 of the 24 baseline values are removed the baseline is steady; and there is still a significant structural break after the onset of infusions. The difference of each value from the mean of the process to that point now fluctuates around 0 during baseline (right lower graph).

Table 2 Patients with change in speed of repetitive tongue or jaw movements, word repetition and in sustained elevation of palate during subacute administration of a TRH analogue (RX77368)

<table>
<thead>
<tr>
<th>Case No</th>
<th>Lateral Magnit</th>
<th>Dur</th>
<th>Protrusion Magnit</th>
<th>Dur</th>
<th>Ticker Magnit</th>
<th>Dur</th>
<th>Pepper Magnit</th>
<th>Dur</th>
<th>Magnit</th>
<th>Dur</th>
<th>Magnit</th>
<th>Dur</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>30 (2.4–6.3)</td>
<td>9</td>
<td>54 (2.1–6.6)</td>
<td>17</td>
<td>2.6 (2.1–3.6)</td>
<td>15</td>
<td>4.4 (2.6–6.0)</td>
<td>17</td>
<td>2.8 (2.2–3.3)</td>
<td>14</td>
<td>NC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(8.8 SD 0.4)</td>
<td></td>
<td>(6.4 SD 0.3)</td>
<td></td>
<td>(4.3 SD 0.2)</td>
<td></td>
<td>(4.1 SD 0.1)</td>
<td></td>
<td>(4.1 SD 0.2)</td>
<td></td>
<td>(24 SD 4.1)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>5.1 (2.9–9.8)</td>
<td>80</td>
<td>2.2 (2.1–2.5)</td>
<td>67</td>
<td>6.6 (2.3–7.5)</td>
<td>80</td>
<td>4.7 (2.4–6.5)</td>
<td>80</td>
<td>4.2 (2.6–7.0)</td>
<td>10</td>
<td>NC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(8.3 SD 0.5)</td>
<td></td>
<td>(7.3 SD 1.1)</td>
<td></td>
<td>(7.1 SD 0.4)</td>
<td></td>
<td>(6.6 SD 0.3)</td>
<td></td>
<td>(7.9 SD 0.4)</td>
<td></td>
<td>(8.9 SD 2.1)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>3.3 (2.6–3.7)</td>
<td>4</td>
<td>NC</td>
<td></td>
<td>2.2 (2.1–2.7)</td>
<td>4</td>
<td>3.7 (2.1–5.9)</td>
<td>5</td>
<td>3.7 (2.1–5.9)</td>
<td>4</td>
<td>NC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(5.5 SD 0.4)</td>
<td></td>
<td>(7.6 SD 0.8)</td>
<td></td>
<td>(7.6 SD 0.8)</td>
<td></td>
<td>(7.9 SD 0.4)</td>
<td></td>
<td>(7.9 SD 0.4)</td>
<td></td>
<td>(8.4 SD 1)</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>2.8 (2.1–4.1)</td>
<td>2</td>
<td>3.0 (2.3–3.5)</td>
<td>2</td>
<td>2.1 (2.4–4.0)</td>
<td>3</td>
<td>NC</td>
<td></td>
<td>2.6 (2.1–3.2)</td>
<td>4</td>
<td>NC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(6.3 SD 0.3)</td>
<td></td>
<td>(5.4 SD 0.3)</td>
<td></td>
<td>(6.5 SD 0.4)</td>
<td></td>
<td>(5.4 SD 0.4)</td>
<td></td>
<td>(5.4 SD 0.4)</td>
<td></td>
<td>(8.4 SD 1)</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>NC</td>
<td></td>
<td>NC</td>
<td></td>
<td>2.7 (2.1–3.5)</td>
<td>12</td>
<td>NC</td>
<td></td>
<td>(4.8 SD 0.3)</td>
<td></td>
<td>(4.8 SD 0.3)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(4.6 SD 0.5)</td>
<td></td>
<td>(5.3 SD 0.9)</td>
<td></td>
<td>(4.2 SD 0.3)</td>
<td></td>
<td>(4.8 SD 0.1)</td>
<td></td>
<td>(4.8 SD 0.1)</td>
<td></td>
<td>(7.9 SD 1.5)</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>NC</td>
<td></td>
<td>NC</td>
<td></td>
<td>(3.9 SD 0.3)</td>
<td></td>
<td>NC</td>
<td></td>
<td>3.7 (2.1–7.1)</td>
<td>11</td>
<td>5.5 (2.1–7.9)</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>(7.3 SD 1.0)</td>
<td></td>
<td>(5.6 SD 1.3)</td>
<td></td>
<td>(4.3 SD 0.1)</td>
<td></td>
<td>(3.2 SD 0.1)</td>
<td></td>
<td>(3.2 SD 0.1)</td>
<td></td>
<td>(4.1 SD 0.9)</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>ND</td>
<td></td>
<td>2.8 (2.1–3.9)</td>
<td>38</td>
<td>NC</td>
<td></td>
<td>NC</td>
<td></td>
<td>3.1 (2.3–12)</td>
<td>38</td>
<td>2.4 (2.3–5)</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>(6.7 SD 0.5)</td>
<td></td>
<td>(6.6 SD 0.5)</td>
<td></td>
<td>(5.2 SD 0.5)</td>
<td></td>
<td>(3.2 SD 0.1)</td>
<td></td>
<td>(3.2 SD 0.1)</td>
<td></td>
<td>(8.4 SD 0.9)</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>NC</td>
<td></td>
<td>3.7 (2.9–5.6)</td>
<td>19</td>
<td>2.1 (2.1–3.3)</td>
<td>1</td>
<td>NC</td>
<td></td>
<td>2.5 (2.1–3.1)</td>
<td>5</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(6.9 SD 0.4)</td>
<td></td>
<td>(6.4–0.4)</td>
<td></td>
<td>(5.2 SD 0.5)</td>
<td></td>
<td>(7.6 SD 0.4)</td>
<td></td>
<td>(7.6 SD 0.4)</td>
<td></td>
<td>(8.4 SD 1.4)</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>NC</td>
<td></td>
<td>NC</td>
<td></td>
<td>3.5 (3.3–4.8)</td>
<td>1</td>
<td>NC</td>
<td></td>
<td>2.5 (2.1–3.1)</td>
<td>5</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(6.3 SD 1.2)</td>
<td></td>
<td>(5.0 SD 0.8)</td>
<td></td>
<td>(4.1 SD 0.2)</td>
<td></td>
<td>(5.6 SD 0.4)</td>
<td></td>
<td>(5.6 SD 0.4)</td>
<td></td>
<td>(5.6 SD 0.4)</td>
<td></td>
</tr>
</tbody>
</table>

For each patient and parameter the first magnitude value is the median and (range) of the best of three replications of all timed measurements outside 2SD of the whole period of infusions. These values are normalised as standard deviation units from mean baseline (= deterioration). The second magnitude value, underneath and in brackets, gives the absolute mean baseline, SD (in seconds) for that parameter and patient. MAGNIT = Magnitude. DUR = Maximum duration of response (days), NC = No change, ND = Not done. The time course of changes in tongue protrusion in patients 1, 3 and 10 is shown in figure 5.
speech, cramps and spasticity. A summary of all results is shown in table 3.

**Bulbar functions**

**Speech** All 10 patients with dysarthria had various degrees of improvement in their speech. One patient with dysphonia also improved and in another anarthria did not change. Improvement started 1–6 hours after the beginning of infusions. It was described as clearer speech, stronger, less nasal voice, lighter tongue or less effort needed to talk. This change was scored as 3 in three patients, as 2 in four patients and as 1 in the remaining three. Except for two patients whose speech remained better for 20 and 70 days after the last infusion, the maximum duration of improvement after each infusion ranged from 2 to 7 days (median 4 days). In three patients the response was only seen with the first 2–4 infusions. Of those with improvement in speech it was seen in all with 0-2 mg/kg or more, in 70% with 0-15 mg/kg, in 20% with 0-1 mg/kg and in none of the patients who received saline (n = 3). Increasing the dose above 0-2 mg/kg did not increase the degree of response or number of responders, although it increased the side effects. Figure 3 shows cumulative sums for word repetition in all patients (Method B).

**Respiration** Changes in respiratory parameters occurred in six of 14 patients tested. Four of them had bulbar signs. VC improved in five patients. In one of them there was initial deterioration with higher doses associated with more side effects followed by improvement with lower doses. In the other VC deteriorated. The time course of these changes is shown in fig 4. Four of these patients also had improvement (33–170% of mean baseline) in MEP or MIP (patients 1, 5, 9 and 10). Peak flow deteriorated (up to 37%) in two patients. One of them (case 2) was asthmatic and had also deterioration (up to 35%) in maximal respiratory pressures, the other (case 3) had significant side effects.

**Other Bulbar Functions** The range of jaw, tongue and facial movements improved moderately in 4/7 patients who had spasticity of relevant muscles. In one patient jaw clonus disappeared 24 hours after each infusion for 1–2 days. Quantitative measurements of other bulbar functions tested showed changes in 9/11 patients (table 3). Figure 5 exemplifies the time course of changes for tongue protrusion. Swallowing improved (one grade) in three cases (for 1, 17 and 80 days) and deteriorated (one grade) in another (for 1 day).

The number of patients who improved and deteriorated for each bulbar function by methods A, B, C1 and C2 is shown in fig 6. All six measures of agreement (P0, P1, P2, A, λ, and K) were consistent. Among these, K has statistical properties and its values were 0-56 (method B), 0-39 (method C1) and 0-29 (method C2). All values of K were significant at p < 0-001 indicating overall agreement in detection of changes in bulbar function by each method relative to method A. There was also good agreement in each individual patient between method A and B (K = 0-51, p < 0-03).

**Cramps and spasticity** Cramps improved significantly from grade 3 to 1 in five of nine patients. This lasted for a median of 2 weeks (range 1–7)...

### Table 3 Results summary

<table>
<thead>
<tr>
<th>Case No</th>
<th>Subjective</th>
<th>Deter'd</th>
<th>Objective*</th>
<th>Deter'd</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Sp, swallow, cramps</td>
<td>Nil</td>
<td>Sp, TM, WR, JM, VC, MEP</td>
<td>Nil</td>
</tr>
<tr>
<td>2</td>
<td>Sp, swallow, cramps</td>
<td>Nil</td>
<td>SP, TM, WR, JM</td>
<td>PF, MEP, MIP</td>
</tr>
<tr>
<td>3</td>
<td>Sp, stiffness</td>
<td>Nil</td>
<td>Sp, spast, TM, WR, JM</td>
<td>PF, VC</td>
</tr>
<tr>
<td>4</td>
<td>Sp, stiffness</td>
<td>Strength</td>
<td>Sp, spast, TM, WR, JM</td>
<td>Nil</td>
</tr>
<tr>
<td>5</td>
<td>Strength (arms), cramps</td>
<td>Nil</td>
<td>PF, MEP, VC, ADL, MVC</td>
<td>VC (high doses)</td>
</tr>
<tr>
<td>6</td>
<td>Stiffness, cramps</td>
<td>Nil</td>
<td>ADL</td>
<td>MVC</td>
</tr>
<tr>
<td>7</td>
<td>Breathing, Sp, cough</td>
<td>Nil</td>
<td>Sp, VC</td>
<td>Nil</td>
</tr>
<tr>
<td>8</td>
<td>Sp, stiffness</td>
<td>Nil</td>
<td>Sp, WR, JM Spast (late)</td>
<td>MEP, spast (early)</td>
</tr>
<tr>
<td>9</td>
<td>Sp</td>
<td>Nil</td>
<td>Sp, JM, PM, MIP, VC</td>
<td>Nil</td>
</tr>
<tr>
<td>10</td>
<td>Sp, swallow</td>
<td>Nil</td>
<td>Sp, JM, TM, MVC, swallow</td>
<td>PM</td>
</tr>
<tr>
<td>11</td>
<td>Stiffness</td>
<td>Swall, strength</td>
<td>Spast</td>
<td>MVC, swallow</td>
</tr>
<tr>
<td>12</td>
<td>Breathing, cough, cramps, strength walking</td>
<td>Nil</td>
<td>VC, MIP, ADL</td>
<td>Nil</td>
</tr>
<tr>
<td>13</td>
<td>Nil</td>
<td>Nil</td>
<td>Nil</td>
<td>MVC</td>
</tr>
<tr>
<td>14</td>
<td>Sp, stiffness</td>
<td>Strength</td>
<td>TM, WR, JM, spast</td>
<td>Nil</td>
</tr>
<tr>
<td>15</td>
<td>Sp, stiffness</td>
<td>Nil</td>
<td>JM, WR</td>
<td>Nil</td>
</tr>
<tr>
<td>16</td>
<td>Sp, strength (legs), walking</td>
<td>Nil</td>
<td>ADL</td>
<td>Nil</td>
</tr>
</tbody>
</table>

*For quantitative data method A (see methods) is given.

Sp = Speech, Swall = Swallowing, Spast = Spasticity (limbs), ADL = Activities of daily life, TM = Tongue movement, WR = Word repetition, PM = Palatal movement, JM = Jaw movement, MVC = Maximal voluntary contraction (seconds in 3 muscles and > 30% of muscles tested), VC = Vital capacity, PF = Peak flow, MEP = Maximal inspiratory pressure, MIP = Maximal expiratory pressure.
Subacute administration of a TRH analogue (RX77368) in motorneuron disease: an open study

Muscle tone in limbs diminished in five of eight patients with spasticity. This was seen 2–24 hours after the infusions started and lasted for 2–14 days, (median 7). In one (patient 8) with sustained unilateral ankle clonus, spasticity increased with bilateral sustained clonus immediately after each infusion and it decreased a day after infusions with disappearance of clonus. Although these changes were associated with better performance in ADL tests in two patients (see over) there were no major functional changes.

Fig 3  Cumulative sums for word repetition (ticker) in all tested patients. The numbers inside the plot indicate case numbers (table 1). The arrows indicate first and last infusion of RX77368. Note improvement (decrease in time to perform the test resulting in values below critical bounds) in patients 1, 2, 3, 4, 8, 10, 15. Patient 9 deteriorated and no significant change was seen in patient 14 and 16.
Muscle force There were no significant changes in MRC grading. Out of 137 muscles tested serially in 13 patients (median 18 days) with dynamometry, MVC changed at least twice during the whole infusion period in 46% (18% improved, 28% deteriorated). The proportion of muscles changing in different subgroups were flexors 63%, extensors 42%, proximal 48%, distal 35%, axial 64%, upper limbs 41%, lower limbs 48% and hand 25%. Changes in three or more muscles and more than a third of muscles tested was seen in 5/13 patients (improvement in two cases, deterioration in three). The percentage of muscles which changed repeatedly with at least three infusions was 27% (12% improved, 15% deteriorated). The maximum duration of improvement or deterioration was 5 and 8 days respectively. Deterioration was more often seen with doses associated with more side effects. These changes were of no major functional
made. There remained subjective improvement in patients during infusions T4 170% compared to saline
of moderate weakness respectively 24 occasions (nine infusions showed the other a
ADL
Of nine patients suitable for ADL testing, two
with moderate weakness in upper limbs (mild spasticity in one) showed improvement in timed zipping
and/or buttoning during the infusions. Two patients with moderate weakness (mild spasticity in one) in the
legs showed improvement in timed walking and rising from a chair (one only with the first three infusions,
the other up to a week after the last infusion). There was subjective improvement in three of these patients.
No subjective or objective changes were noted after saline infusions.

Other changes Fasciculations increased in six patients during infusions and decreased in two
approximately 1 day after infusions. No changes were seen in reflexes or plantar responses. Norris scale did
not change during or after infusions.

Thyroid function Patient 7 was hypothyroid and his T4 remained unchanged. In the others, weekly serum
T4 (n = 54) and T3 (n = 34) measurements were made. There was a median increase of 28-5% (n = 28,
range -13% to +130%) and 72% (n = 18, range 0 to 170%) compared to baseline in serum T4 and T3
respectively 24 hours after individual infusions. On 10 occasions (nine patients) these were above the normal
range. The measurements 48 hours or more after the infusions showed a median change of -8% (n = 26,
range -47% to 33%) for T4 and +7% (n = 16, range -33% to +80%) for T3. Serum T3 remained
within normal range. TSH increased temporarily in two patients and was suppressed (below normal
range) in half of the patients remaining so up to one week after the last infusion. There was no relationship
between rise in serum thyroxine and clinical response or severity of side effects.

Adverse effects Side effects included shivering and hot and cold feelings (n = 16 each); tickling in the
throat (n = 12); cough, nausea (n = 11 each); excessive tiredness (n = 10); sweating (n = 8); hyper-
salivation (n = 7); rhinorrhea, dryness of the mouth (n = 4 each); excessive yawning (n = 3); vomiting,
itching, urgency and frequency of micturition (n = 2 each); thirst and heartburn (n = 1 each). Moderate to
severe side effects were seen in 58% with doses above 0·2 mg/kg, in 40% with 0·2 mg/kg (5/6 had severe
bulbar palsy), only in one patient (17%) with severe bulbar palsy with 0·15 mg/kg and in none with
0·1 mg/kg. They were predominantly seen during and within 1 hour after the infusions but occasionally con-
tinued for up to 14 hours. In patients with repeated daily infusions the intensity of side effects decreased
with each infusion in the first 3 to 6 days and then increased again. This was less evident in patients with
longer interval between infusions.

There was no change in BP, pulse and oral tempera-
ture outside the normal range except for a temporary increase in BP in a patient with a history of
hypertension. There was no change in liver function tests, FBC and urea and electrolysis during or after infusions.

**Discussion**

The changes in speech, respiration, muscle force and spasticity observed in this study are similar to our previous acute controlled trial. A biological rather than a placebo effect is also supported by (1) the temporal relationship of the changes to the infusions, (2) the reproducibility of the response, (3) the lack of response to small doses and to saline infusions, (4) the associated objective findings, (5) the magnitude of the responses seen was beyond the degree of placebo effect observed in our previous controlled study. We have not seen significant improvement in speech or respiration with placebo. In addition, repeated exercise tests in the first 2 days followed by a prolonged baseline made any significant learning effect less likely. When they still occurred, individual correction of the baselines with the cumulative sum test, still yielded similar overall results to the other two methods of analysis used (see methods).

Improvement in speech could be maintained in eight of 12 patients who responded for up to 3 months. Two of the three who improved only with the first 2-4 infusions had them daily. Improvement in tongue or jaw (or palate in one patient) movements was only seen in patients with spasticity of relevant muscles and correlated with changes in speech. Improvement in VC in five patients lasted for a maximum of 3 days after the infusions except in one patient in whom it was maintained for 3 months. Both the loss of response in speech with daily infusions and the less evident changes in VC with repeated infusions suggest receptor down regulation and highlight the importance of careful choice of frequency of administration in future large scale longer term studies.

Deterioration in peak flow and VC was seen in two
Subacute administration of a TRH analogue (RX77368) in motorneuron disease: an open study

![Graph](image)

Fig 7 Time course of changes in dynamometry measurements of force. All muscles tested in case 12(a) and case 11(b). The layout of the graphs is similar to fig 4. SE = Side effects (+ mild, ++ moderate). Top: Muscles which changed (improvement in patient A, deterioration in patient B) Bottom: Muscles which did not change. Patient A had also improvement in timed walking and rising from a chair. For muscle name abbreviations see methods; R = right, L = left. The dose range in the top left corner, in mg/kg, is the same for the two patients and the size of the arrows correlates with the dose given.

patients. Studies with native TRH have shown improvement in VC. Exacerbation of asthma has been reported. A mean 35% decrease in FEV, with TRH compared to saline was found in five of 25 patients in one study and bronchospasm produced by hyperthyroidism was suggested as the mechanism. Both our two patients with decreased peak flow had raised serum T4 above the normal range. The effect might also be related to a direct effect of TRH on smooth muscle.

The effects seen on cramps and spasticity could be maintained for up to 4 weeks after the last infusion. In a few patients we saw initial increase, followed by decrease, in spasticity. Similar observations have been made with TRH over a shorter period by others. The response in muscle force was patchy and transient. Some patients had deterioration in one or more muscles and improvement in others. In two patients initial deterioration in some muscles was followed by transient improvement 24-48 hours later. This initial deterioration was associated with more side effects, although the assessments were made at times when they were minimal. In one patient five muscles improved initially but deteriorated with higher doses and again improved with lower doses 4 days later. These patterns of response make analysis of data in large scale studies difficult. Symptomatic improvement for up to 32 weeks with subcutaneous and intravenous open administration of native TRH respectively has been reported. Daily injection of small subcutaneous (25 mg) and intramuscular (4 mg) and of larger intramuscular (150 mg) doses were reported as of no benefit in controlled trials. In one of them proximal muscle strength was improved after 16 weeks and in another fixed assessment points were not stated, reliable baselines were not defined and assessment methods may not have been sensitive enough. In a controlled study on 14 responders with IV TRH every other day the TRH group had less deterioration than the saline group over 10 weeks in jaw muscle strength, vital capacity, certain tests of lower extremity function and exercise capacity. One group reported no overall benefit with intrathecal TRH over 6 months whilst another suggested a slowing of the rate of deterioration in muscle strength over 12
months. No arrest of disease progression has been seen for TRH and RX77368. One controlled study\textsuperscript{11} with daily im TRH for 2 months showed no slowing of the rate of deterioration by 80% or more. However, whether a lesser degree of slowing of the rate of deterioration (globally or for certain specific functions) is possible, is not known.

A given drug may be therapeutically useful in MND if, in the absence of serious side effects it is found to (1) reduce mortality, and/or (2) prolong survival time, and/or (3) reduce significantly the rate of deterioration in some or all affected functions, and/or (4) produce symptomatic improvements which can be maintained for prolonged periods. One or more of these conditions can be fulfilled by such a drug acting on the (so far unknown) cause of the disease and/or on the mechanisms leading to motor neuron loss and/or on the mechanisms mediating the symptomatic effects of motor neuron loss or dysfunction. In turn, these possible actions may be exerted on (1) cortical motor neurons and/or their connections and/or (2) bulbar motor neurons and/or their connections and/or (3) spinal motor neurons and/or their connections. It follows that, in MND short lived improvements in function do not necessarily represent therapeutic benefit just as much as lack of detectable symptomatic improvement does not necessarily mean lack of such benefit. Since the usual cause of death in MND is respiratory failure hypothetical drugs acting mainly on limb motor neurons might help disability without affecting survival time or mortality. Conversely, drugs acting mainly on bulbar and high cervical motor neurons might increase survival time although somatic disability would remain unchanged.\textsuperscript{1}

Our data suggest that RX77368 may have a more prominent action on bulbar function and less in somatic muscle force, and that beneficial effects may be maintained for several weeks in some patients. Administration of RX77368 did not result in dramatic change in functional status; the effects were slight or moderate but definite. A possible practical value of this or other analogues as symptomatic treatment will need confirmation of our results in a larger series, an acceptable incidence of side effects and a demonstration of persistence of the benefits seen for a few months. Longer term controlled studies with RX77368 on the course of the disease are also required but attention to dose, frequency of administration and assessment methods will be critical.

This work was supported by Grants from the Motor Neurone Disease Association of Great Britain, the NW Thames Regional Health Authority and the Special Trustees of Westminster and Roehampton Hospitals.

We thank Drs C Hawkes, R C Hughes, J Jestico, C Kennard, R McKeran, E Reynolds, A Turner and S Wilson who kindly referred patients for this study and Prof R Farmer for statistical advice.

References


16 Engel WK, Van den Bergh P, Askanas V. Subcutaneous
Subacute administration of a TRH analogue (RX77368) in motorneuron disease: an open study


References


J.-J. Forst and Lasègue's sign

Sciatica has been recognised since Greek and Roman times, but only since the paper of Mixter and Barr1 has its commonest cause been recognised as a prolapsed lumbar disk.

Ernest Charles Lasègue (1816–83), impetuous student friend of Claude Bernard, favourite pupil of Trousseau, won his agrégation (about GPA) in 1853. Physician to the Salpêtrière he was “forever after malingerers”. The notion of uncovering malingerers who simulated sciatica, took root when he watched his son in law Cesbron tuning his violin: “is not the string stretched over the bridge like the sciatic nerve which is made taut on the ischium when the lower extremity is elevated?”

Dr J.-J. Forst’s doctoral thesis of 18812 described the sign that his teacher Lasègue had observed but never published. There is however a contemporary description by a Serbian physician, Laza Lazarevic in 18803 of “Ischias postica contunnii” with restricted straight leg raising. It maybe be coincidental that Kernig’s sign which is often confused with it, was described in 18844.

Forst described his master’s test in two stages:

“the patient is placed on the bed in the supine position, and we take the foot of the affected limb in one hand... holding the leg in extension, we flex the thigh on the pelvis. Raising the limb only a few centimetres produces a sharp pain at the level of the sciatic notch... We replace the limb and proceed to another manoeuvre which is only a confirmatory test... If we now flex the leg on the thigh, we can flex the thigh on the pelvis without producing any painful sensation.” Forst stressed the precautions of flexing the thigh slowly and sliding the heel on the bed and securing cooperation to relax the limb completely.

“What is happening?... the sensation of pulling is very probably due to compression of the sciatic nerve by muscular contraction. On the other hand, if we flex the leg on the thigh, we paralyse the extensors of the thigh on the pelvis.... there is greater ease in raising the limb with less compression of the sciatic nerve.... We consider this sign to be pathognomonic of sciatica, for we have not found it in any other affection of that region.”

In 1884, De Beurmann espoused the current explanation: that the sign is due to stretching of the sciatic nerve itself rather than sciatic compression by the mass muscle.

References